Online Clinical Pathway for Chronic Kidney Disease Management in Primary Care: A Retrospective Cohort Study

Maoliosa Donald
University of Calgary

Michelle D. Smekal
University of Calgary

Meghan J Elliot
University of Calgary

Kerry McBrien
University of Calgary

Robert Weaver
University of Calgary

Braden J. Manns
University of Calgary

Marcello Tonelli
University of Calgary

Aminu Bello
University of Alberta

Sharon E. Strauss
University of Toronto

Nairne Scott-Douglas
University of Calgary

Kailash Jindal
University of Alberta

Brenda R. Hemmelgam (✉ Brenda.Hemmelgam@ahs.ca)
University of Alberta

Research Article

Keywords: chronic kidney disease, primary care, clinical pathway, quality improvement, knowledge translation

DOI: https://doi.org/10.21203/rs.3.rs-645959/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Clinical pathways aim to improve patient care. We sought to determine whether an online chronic kidney disease (CKD) clinical pathway was associated with improvements in CKD management.

Methods

We conducted a retrospective pre/post population-based cohort study using linked health data from Alberta, Canada. We included adults 18 years or older with mean estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m$^2$. The primary outcome was measurement of an outpatient urine albumin creatinine ratio (ACR) in a 28-day period, among people without a test in the prior year. Secondary outcomes included use of guideline-recommended drug therapies (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and statins).

Results

The study period spanned October 2010 to March 2017. There were 84 independent 28-day periods (53 pre, 31 post pathway implementation) including 345,058 adults. The population was predominantly female (56%) with median age 77 years; most had category 3A CKD (67%) and hypertension (82%). In adjusted segmented regression models, the increase in the rate of change of ACR testing was greatest in Calgary zone (adjusted OR 1.19 per year, 95% CI 1.16–1.21), where dissemination of the pathway was strongest; this increase was more pronounced in those without diabetes (adjusted OR 1.25 per year, 95% CI 1.21–1.29). Small improvements in guideline-concordant medication use were also observed.

Conclusions:

Following implementation of an online CKD clinical pathway, improvements in ACR testing were evident in regions where the pathway was most actively used, particularly among individuals without diabetes.

Background

Chronic kidney disease (CKD) affects approximately 11% of adults in Canada and is associated with considerable morbidity, mortality, and health care costs $^1$. Early intervention, including targeted testing for albuminuria and medical management with angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB) and statins, where indicated, can delay CKD progression $^2$–$^5$. Despite availability of effective therapies, important care gaps are evident $^6$, with over 80% of Canadian adults with CKD not tested for albuminuria and approximately 50% of older adults with CKD not prescribed guideline-recommended medications $^8$, $^9$. Since over 90% of patients with CKD are managed in primary care $^10$, and primary care providers have indicated the need for concise point-of-care guidelines $^11$, an online CKD clinical pathway (www.ckdpathway.ca) was developed to support guideline-concordant care in community settings $^{12,13}$.

Clinical pathways are effective tools to streamline clinical guidelines and improve efficiency of care, and have become increasingly common particularly in hospital settings $^{14,15}$. Despite widespread implementation, the effectiveness of clinical pathways targeted toward community practice settings has not been well studied $^{14,16}$. Furthermore, while several pathways have targeting aspects of CKD identification and/or management, the majority of these are static, may not be updated to incorporate current guidelines, and have not undergone rigorous evaluation $^{16}$. We aimed to determine whether implementation of an online CKD clinical pathway was associated with improvements in CKD management, including targeted urine albumin-creatinine ratio (ACR) testing and guideline-recommended drug therapy (ACEi, ARB and statins) $^2$.

Methods

We conducted a retrospective population-based pre-post cohort study using linked administrative health and laboratory data from Alberta, Canada $^{17}$ (Fig. 1). The CKD pathway was launched November 5, 2014. The pre-intervention period comprised 53 28-day periods from October 8, 2010 to November 4, 2014, and the post period comprised 31 28-day periods from November 5, 2014 to March 24, 2017. Each 28-day period included Alberta residents aged 18 years or older with mean estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m$^2$, using all outpatient serum creatinine measurements in the prior year. We excluded people who had commenced dialysis or received a kidney transplant prior to the last day of the 28-day period. We chose 28-day periods rather than months given variability in laboratory testing by day of week, and variability in the number of weekdays in a calendar month year to year. Years were divided into thirteen 28-day periods, with the extra day (two in leap years) assigned to the final period.

The online CKD Pathway

The CKD pathway was developed by a multidisciplinary group of stakeholders to provide access to concise point-of-care guidelines for the identification, medical management, and referral of adults with CKD $^{12}$. The pathway incorporated relevant clinical practice guidelines $^{18}$–$^{23}$ and was rigorously developed and tested prior to implementation $^{12}$. The primary goals of the pathway were to improve early identification (through targeted ACR testing of high-risk patients) and appropriate medical management (prescription of ACEi/ARB and/or statin, where indicated). Although the CKD...
pathway is freely available ([www.ckdpathway.ca](http://www.ckdpathway.ca)), implementation was targeted to primary care providers in Alberta. A multifaceted strategy was used to support implementation. Website analytics showed that pathway uptake was consistently greatest in Calgary, Alberta, with nearly three times as many users (31%) compared to Edmonton (11%), a similar-sized city in Alberta.

**Outcomes**

The primary outcome was assessment of albuminuria as defined by an outpatient random urine ACR measurement, in a 28-day period, among people without a test in the prior year (to reflect new assessment of albuminuria). Secondary outcomes were related to CKD management and included use of an ACEi/ARB or statin, defined as dispensation of a prescription during a 28-day period. ACEi/ARB use was assessed in individuals with diabetes as well as in those without diabetes but whose most recent ACR was > 300 mg/g (30 mg/mmol), indicating severe (A3) albuminuria. Statin use was assessed in individuals with diabetes, and in those without diabetes who were 50 years of age or older (as per guideline recommendations). All outcomes were treated as binary.

**Measurement of covariates**

Diabetes, hypertension and other comorbidities were identified from physician claims and hospital discharge records using validated algorithms. Albuminuria was defined using ACR and categorized as A1 (< 30 mg/g), A2 (30–300 mg/g) and A3 (> 300 mg/g). We determined dates of kidney transplants and dialysis initiation by linking to provincial dialysis and transplant registry data. We categorized patients using geographically defined health zones in Alberta into three categories (Calgary, Edmonton, Other) based on postal code of the person's residence (Figure S1). We also linked aggregated 2011 and 2016 federal census data to obtain neighborhood income quintile and urban/rural location. Calgary and Edmonton zones each include a large metropolitan center (> 1 million residents) and smaller neighboring towns. The Other category includes zones in South, North, and Central Alberta, which are primarily rural with 1–2 smaller cities in each region (< 100,000 residents). We defined all covariates at the beginning of each 28-day period.

**Statistical analysis**

We determined the association between CKD pathway implementation and outcomes using segmented regression analysis. We used logistic regression within a generalized estimating equation framework to account for individuals’ repetition across periods, with an exchangeable covariance matrix and with robust standard errors that are insensitive to misspecification of the correlation matrix. We adjusted models for age, sex, eGFR category, albuminuria category (where relevant), comorbidities, neighborhood income quintile, rural/urban residence and the 13 periods within the year, to account for seasonality. We included a term for the rate of change of the outcome in the pre period (slope, expressed as an odds ratio per year) and modeled the effect of the intervention by including a term for the change in slope between pre and post periods, also expressed as an odds ratio per year. We did not include a term for a sudden increase in referrals, based on our understanding of the way the intervention would affect the outcome, which is key to determining how to model the effects of an intervention. Specifically, we thought that physicians would gradually start referring more patients for ACR testing as awareness of the CKD Pathway increased.

Given differences in pathway use trends, we assumed uptake of the CKD pathway varied across Alberta. We tested for effect modification by health zone (Calgary, Edmonton, and Other zones) by including terms for zone and interactions with pre-intervention slope and pre-post change in slope. If the interaction terms between zone and pre-post change in slope were statistically significant, results were reported by zone.

In sensitivity analyses for the primary outcome, we restricted the cohort to people whose mean eGFR was calculated from at least two serum creatinine measurements in the prior year, to reduce potential misclassification of CKD. In other sensitivity analyses, we analyzed the prescription drug outcomes using a modified calendar quarter (three quarters comprising three 28-day periods and one quarter comprising four 28-day periods) rather than a 28-day period, because a 28-day period captures only a portion of prescriptions for an individual. Most individuals were prescribed an ACEi, ARB or statin for a 30-, 90- or 100-day period.

All statistical analyses were conducted in Stata 16 (StataCorp, College Station, TX). The study was approved by the Health Research Ethics Board of the University of Calgary.

**Results**

The 84 independent 28-day periods included 10,343,666 patient records corresponding to 345,058 unique patients. Characteristics of the overall cohort and the sub-cohort used for analysis of the primary outcome (i.e., those without a urine ACR in the prior year) are provided in Table 1 and Fig. 2. The overall cohort was predominantly female (56.4%), with median age 77 years. The majority had category 3A CKD (66.8%), with a high prevalence of hypertension (82.2%) and diabetes (33.0%). For analysis of secondary outcomes, the sub-cohort of people with diabetes was almost 50-fold larger than the sub-cohort of people with severe albuminuria and no diabetes (Table S1). Compared to people with severe albuminuria and no diabetes, people in the diabetes cohort were older (median age 76.5 years), more likely to be female (50.6%) and to have an eGFR > 45ml/min/1.73m² (57.3%). People in the sub-cohort who were older than 50 years and without diabetes were more likely to be female (59.5%) with a lower prevalence of comorbidities than people with diabetes.
Table 1: Characteristics of the overall cohort, and the sub-cohort eligible for the primary outcome (no ACR measurement in the prior year), (% unless otherwise noted).

| Characteristic                                      | Overall cohort (N = 10,343,666 patient records) | Sub-cohort eligible for the primary outcome (N = 7,898,542 patient records) |
|-----------------------------------------------------|-------------------------------------------------|--------------------------------------------------------------------------|
| Number of unique patients                           | 345,058                                         | 328,248                                                                  |
| Number of times each patient appears in the cohort, median (IQR) | 22 (11,46)                                      | 16 (8,36)                                                                |
| Age in years, median (IQR)                          | 76.8 (68.2, 84.1)                               | 77.7 (68.7, 84.9)                                                       |
| Female                                              | 56.4                                            | 58.4                                                                     |
| Health zone                                         | 34.9                                            | 36.4                                                                     |
| Calgary Zone                                        | 29.9                                            | 27.7                                                                     |
| Edmonton Zone                                       | 35.2                                            | 35.9                                                                     |
| Other zones                                         |                                                 |                                                                          |
| Number of times each patient appears in the cohort, median (IQR) | 22 (11,46)                                      | 16 (8,36)                                                                |
| Age in years, median (IQR)                          | 76.8 (68.2, 84.1)                               | 77.7 (68.7, 84.9)                                                       |
| Female                                              | 56.4                                            | 58.4                                                                     |
| Health zone                                         | 34.9                                            | 36.4                                                                     |
| Calgary Zone                                        | 29.9                                            | 27.7                                                                     |
| Edmonton Zone                                       | 35.2                                            | 35.9                                                                     |
| Other zones                                         |                                                 |                                                                          |
| Patient records with an ACR measurement             | 3.05%                                           | 1.39%                                                                   |
| Most recent ACR in past year                        | 13.5                                            | —                                                                        |
| Normal/mild (A1: <30 mg/g)                          | 6.8                                             | —                                                                        |
| Moderate (A2: 30–300 mg/g)                          | 3.3                                             | —                                                                        |
| Severe (A3: >300 mg/g)                              | 76.4                                            | 100                                                                     |
| eGFR category (ml/min/1.73m²)                       |                                                 |                                                                          |
| 3a (45–59)                                          | 66.8                                            | 68.7                                                                    |
| 3b (30–44)                                          | 25.1                                            | 24.0                                                                    |
| 4 (15–29)                                           | 7.2                                             | 6.5                                                                     |
| 5 (< 15)                                            | 0.9                                             | 0.9                                                                     |
| Number of outpatient serum creatinine measurements in past year | 45.0                                             | 50.4                                                                    |
| 1                                                   | 35.2                                            | 33.1                                                                    |
| 2–3                                                 | 19.8                                            | 16.5                                                                    |
| ≥4                                                  |                                                 |                                                                          |
| Alcohol misuse                                      | 3.2                                             | 3.2                                                                     |
| Asthma                                              | 4.8                                             | 4.7                                                                     |
| Atrial fibrillation                                 | 17.7                                            | 18.4                                                                    |
| Cancer                                              | 13.7                                            | 14.2                                                                    |
| Chronic heart failure                               | 21.2                                            | 21.5                                                                    |
| Chronic pulmonary disease                           | 26.5                                            | 26.8                                                                    |
| Chronic viral hepatitis B                           | 0.1                                             | 0.1                                                                     |
| Cirrhosis                                           | 0.7                                             | 0.7                                                                     |
| Dementia                                            | 11.5                                            | 13.2                                                                    |
| Diabetes                                            | 33.0                                            | 22.8                                                                    |
| Epilepsy                                            | 2.3                                             | 2.4                                                                     |
| Hypertension                                        | 82.2                                            | 79.8                                                                    |

IQR – interquartile range; ACR – urine albumin/creatinine ratio; eGFR – estimated glomerular filtration rate; TIA – transient ischemic attack
### Characteristic

| Characteristic                       | Overall cohort (N = 10,343,666 patient records) | Sub-cohort eligible for the primary outcome (N = 7,898,542 patient records) |
|--------------------------------------|-------------------------------------------------|--------------------------------------------------------------------------|
| Hypothyroidism                       | 23.1                                            | 23.7                                                                    |
| Inflammatory bowel disease           | 1.8                                             | 1.9                                                                     |
| Irritable bowel syndrome             | 3.2                                             | 3.3                                                                     |
| Multiple sclerosis                   | 0.7                                             | 0.8                                                                     |
| Metastatic cancer                    | 4.0                                             | 4.3                                                                     |
| Myocardial infarction                | 8.3                                             | 8.0                                                                     |
| Parkinson’s disease                  | 2.1                                             | 2.3                                                                     |
| Peripheral vascular disease          | 5.3                                             | 5.2                                                                     |
| Psoriasis                            | 1.3                                             | 1.3                                                                     |
| Rheumatoid arthritis                 | 5.9                                             | 6.2                                                                     |
| Schizophrenia                        | 1.4                                             | 1.5                                                                     |
| Stroke or TIA                        | 20.8                                            | 21.2                                                                    |
| Neighborhood income quintile         | 25.4                                            | 25.1                                                                    |
| 1 (lowest)                           | 22.9                                            | 22.8                                                                    |
| 2                                    | 19.7                                            | 19.8                                                                    |
| 3                                    | 16.0                                            | 16.0                                                                    |
| 4                                    | 15.9                                            | 16.2                                                                    |
| 5 (highest)                          | 0.1                                             | 0.1                                                                     |
| Unknown                              |                                                  |                                                                          |
| Rural residence                      | 77.7                                            | 77.0                                                                    |
| Urban                                | 22.3                                            | 22.9                                                                    |
| Rural                                | 0.1                                             | 0.1                                                                     |
| Unknown                              |                                                  |                                                                          |

IQR – interquartile range; ACR – urine albumin/creatinine ratio; eGFR – estimated glomerular filtration rate; TIA – transient ischemic attack

### Primary outcome: Pre-post change in ACR measurement

Overall the percentage of people with an ACR test in a 28-day period, among those who had not had a measurement in the prior year, was 1.31% in the pre period and 1.51% in the post period. The increase was greatest in the Calgary (1.17–1.50%), followed by Edmonton (1.57–1.80%) and Other zones (1.22–1.30%). In adjusted segmented regression models, interactions between zone and pre-post change in slope for ACR measurement were significant (all P < 0.001), so we calculated zone-specific estimates (Table 2; Fig. 3). In the Calgary zone there was a statistically significant pre-post increase in slope (adjusted OR 1.19 per year, 95% CI 1.16–1.21), while in the Edmonton zone there was a significant pre-post decrease in slope (adjusted OR 0.92 per year, 95% CI 0.89–0.94). Prior to CKD pathway implementation, there was a substantially higher rate of ACR testing in Edmonton zone, which was increasing over time; the decrease in slope following CKD pathway implementation was associated with a stable/slow decline in the rate of ACR testing post-intervention in that zone (Fig. 3). In Other zones, there was little pre-post change in slope.
Table 2
Estimates of the rate of change in ACR measurement in the pre period and the post period, and the pre-to-post change (by zone; in the full cohort and stratified by diabetes).

| Cohort                | Patient records | Zone     | Odds ratios for rate of change per year in ACR measurement |
|-----------------------|-----------------|----------|------------------------------------------------------------|
|                       |                 |          | Pre period OR (95% CI) | Post period OR (95% CI) | Pre to post change OR (95% CI) (outcome) |
| Full                  | 7,898,542       | Calgary  | 1.02 (1.01–1.03)      | 1.21 (1.19–1.23)        | 1.19 (1.16–1.21)                     |
|                       |                 | Edmonton | 1.07 (1.06–1.08)      | 0.98 (0.96–0.99)        | 0.92 (0.89–0.94)                     |
|                       |                 | Other    | 1.02 (1.01–1.03)      | 1.00 (0.99–1.02)        | 0.99 (0.96–1.01)                     |
| Patients with diabetes| 1,798,159       | Calgary  | 1.01 (0.99–1.02)      | 1.10 (1.07–1.12)        | 1.09 (1.06–1.12)                     |
|                       |                 | Edmonton | 1.03 (1.02–1.04)      | 0.94 (0.92–0.97)        | 0.92 (0.89–0.95)                     |
|                       |                 | Other    | 1.00 (0.99–1.02)      | 0.99 (0.97–1.01)        | 0.98 (0.95–1.01)                     |
| Patients without diabetes | 6,100,383 | Calgary  | 1.04 (1.03–1.06)      | 1.30 (1.28–1.33)        | 1.25 (1.21–1.29)                     |
|                       |                 | Edmonton | 1.12 (1.11–1.14)      | 1.01 (0.98–1.03)        | 0.90 (0.87–0.93)                     |
|                       |                 | Other    | 1.04 (1.03–1.06)      | 1.02 (0.99–1.04)        | 0.98 (0.94–1.01)                     |

All P for interactions between zone and the primary outcome were < .001. Adjusted for age, sex, eGFR category, the thirteen 28-day periods, neighborhood income quintile, rural residence, and all comorbidities in Table 1.

Significant interactions between zone and pre-post change were also evident when we stratified by diabetes (all P for interaction < 0.001) (Fig. 4). Overall, the prevalence of ACR testing was higher among those with (3.1%) than those without diabetes (0.9%). Again, there were significant pre-post increases in slope in Calgary zone, significant decreases in slope in Edmonton zone, and little change in Other zones, among those with and without diabetes. The increase in Calgary zone was greater among those without diabetes (adjusted OR 1.25 per year, 95% CI 1.21–1.29) than those with diabetes (adjusted OR 1.09 per year, 95% CI 1.06–1.12).

The pre-post change in slope in Calgary zone corresponded to approximately 800 (95% CI 700–900) additional people tested in the first year, and 2400 (95% CI 2100–2700) in the second year (cohort size 43,000). Of the additional people tested, about three quarters were without diabetes.

Because the segmented regression models were constrained to a change in slope at the time of CKD pathway implementation, we also compared the proportions predicted by the models for each zone against the adjusted proportions with an ACR measurement in each 28-day period from a model with the 84 independent periods as a categorical variable (Figures S2 and S1). While the adjusted proportions for Calgary zone are consistent with the results from the segmented regression (Figure S2), the adjusted proportions for Edmonton zone showed a decrease in ACR testing approximately 2 years after CKD pathway implementation, rather than around the time of the intervention (Figure S1).

The results of the sensitivity analyses for the primary outcome (sub-cohort limited to those with 2 or more serum creatinine measurements in the prior year) were broadly similar to the main analyses (Table S2).

Secondary outcomes:

Pre-post change in ACEi/ARB use

The prevalence of ACEi/ARB use (defined as dispensation of a prescription in a 28-day period) during the study period was 30.4% in the diabetes cohort and 25.8% in the albuminuria cohort. The interaction terms between zone and pre-post change in slope were significant in both cohorts. In the diabetes cohort there was a small but statistically significant pre-post increase in slope in Calgary zone (adjusted OR 1.02 per year, 95% CI 1.00–1.04) and Edmonton zone (adjusted OR 1.02 per year, 95% CI 1.01–1.04) but not in Other zones (Table 3, Figure S4). In the albuminuria cohort, the pre-post change in slope was not significant in any of the zones (Figure S5). The pre-post increase in the diabetes cohort represent an additional 55 (95% CI 9–104) people in Calgary Zone (cohort size 14,600) and 58 (95% CI 18–101) people in Edmonton Zone (cohort size 12,500) dispensed an ACEi/ARB per 28-day period over a one-year timeframe.
Table 3
Estimates of the pre-post change in slope for ACEi/ARB use in a 28-day period: diabetes cohort and no diabetes/severe albuminuria cohorts.

| Zone          | Diabetes (N = 3,414,791 patient records) | No diabetes, A3 albuminuria (N = 70,897 patient records) |
|---------------|------------------------------------------|----------------------------------------------------------|
|               | P for interaction                        | P for interaction                                        |
|               | OR (95% CI) (per year)                   | OR (95% CI) (per year)                                   |
| Overall       | --                                      | --                                                       |
| Calgary Zone  | Ref                                      | 0.91 (0.83–1.00)                                        |
| Edmonton Zone | 0.72                                     | 0.05                                                     |
| Other zones   | 0.02                                     | 0.04                                                     |
|               | 1.02 (1.00-1.04)                         | 1.04 (0.95–1.14)                                        |
|               | 0.99 (0.98–1.01)                         | 1.07 (0.95–1.20)                                        |

Adjusted for age, sex, eGFR category, ACR category (diabetes cohort only), the thirteen 28-day periods, neighborhood income quintile, rural residence, and all comorbidities in Table 1.

In sensitivity analyses, the overall prevalence of ACEi/ARB use in a modified calendar quarter during the study period was 58% in the diabetes cohort and 55% in the no diabetes/albuminuria cohort. In the diabetes cohort, the interactions between zone and pre-post change in the outcome were not significant, and there was a small but statistically significant overall pre-post increase in the outcome (adjusted OR = 1.03 per year, 95% CI 1.02–1.04). In the albuminuria cohort, the interactions were significant. Calgary zone showed a significant decrease from pre to post (adjusted OR = 0.84 per year, 95% CI 0.73–0.96), while the change was not significant in the other two regions (Table S3).

Pre-post change in statin use

The overall prevalence of statin use in a 28-day period during the study period was 12.9% in the no diabetes/older than age 50 cohort and 25.4% in the diabetes cohort. The interaction terms between zone and pre-post change in slope were significant in both cohorts (Table 4, Figures S6, S7). In analysis by zone, there was a small but statistically significant pre-post increase in slope for statin use for Calgary and Edmonton zones but not in Other zones. In both cohorts, the increase was larger in Edmonton zone than in Calgary zone. In the diabetes cohort, the pre-post increase represents an additional 75 people (95% CI 27–118) in Calgary Zone (cohort size 14,600) and 127 people (95% CI 87–167) in Edmonton Zone (cohort size 12,500) who were dispensed a statin per 28-day period, over a one-year timeframe. In the no diabetes/older 50 cohort, it represents an additional 58 people (95% CI 4–112) in Calgary Zone (cohort size 37,000) and 89 people (95% CI 54–125) in Edmonton Zone (cohort size 19,500) who were dispensed a statin per 28-day period, over a one-year timeframe.

Table 4
Estimates of the pre-post change in slope for statin use in a 28-day period, for the diabetes cohort and the no diabetes/over 50 years old cohort.

| Zone           | Diabetes (N = 3,414,791 patient records) | No diabetes, older than 50 (N = 6,895,062 patient records) |
|----------------|------------------------------------------|-------------------------------------------------------------|
|                | P for interaction                        | P for interaction                                          |
|                | OR (95% CI) (per year)                   | OR (95% CI) (per year)                                     |
| Calgary Zone   | Ref                                      | 1.02 (1.01–1.05)                                          |
| Edmonton Zone  | 0.03                                     | 1.06 (1.04–1.08)                                          |
| Other zones    | 0.15                                     | 1.01 (0.99–1.03)                                          |
|                | 1.03 (1.01–1.05)                         | 1.04 (1.03–1.06)                                          |
|                | 1.01 (0.99–1.03)                         | 1.00 (0.99–1.02)                                          |

Adjusted for age, sex, eGFR category, ACR category, the thirteen 28-day periods, neighborhood income quintile, rural residence, and all comorbidities in Table 1.

The prevalence of statin use in a modified calendar quarter during the study period was 48% in the diabetes cohort and 27% in the no diabetes/older than age 50 cohort. In sensitivity analyses, we again found that zone interactions were significant in both cohorts. In both cohorts, there was a significant pre-post increase in slope in all 3 zones, with Edmonton zone showing a slightly larger increase (adjusted OR 1.09 per year, 95% CI 1.07–1.11 in the diabetes cohort; adjusted OR 1.06 per year, 95% CI 1.05–1.08 in the no diabetes/older than 50 cohort; Table S4).

Discussion

We conducted a population-based cohort study to evaluate implementation of an online CKD clinical pathway targeted to primary care providers. In this cohort of 345,058 adults with CKD we found small but statistically significant higher rates of ACR testing in Calgary zone following CKD pathway implementation, particularly among people without diabetes. Small improvements in guideline-recommended pharmacological therapy (ACEi/ARB and statins) were observed in both Calgary and Edmonton zones in most cohorts. While the observed improvements were small, at a population-based level they may have considerable benefit and the pathway itself required minimal resources and time to maintain once established.
Uptake of the CKD pathway was greater in Calgary zone compared to other zones, and may have contributed to the observed increase in ACR testing in that zone. Active dissemination, such as small group education sessions, is a known contributor to uptake of new knowledge amongst physicians; additional dissemination efforts, particularly those that involved outreach visits and were targeted to the needs of the local context, may have improved CKD pathway uptake. There were no significant pre-post changes evident in Other zones (South, Central and North), which encompass the less-populated regions of Alberta. This could be related to fewer dissemination opportunities and the unique challenges experienced treating patients in rural locations, such as access to care barriers and WiFi access and reliability issues. In Edmonton Zone, ACR testing increased steadily in the Pre period and for almost 2 years into the Post period. The relative decrease that occurred at that time may therefore have been unrelated to the CKD pathway implementation.

We also observed a greater increase in ACR testing among individuals without diabetes in the Calgary zone following CKD pathway implementation. Research demonstrates a gap in guideline-concordant CKD care for individuals without diabetes. Despite an increase in ACR testing following implementation, most of these individuals still do not undergo ACR testing, indicating a persisting gap in the application of knowledge regarding management of CKD. Additional dissemination efforts may help to close this gap; however, care for patients with CKD is complex. Patients often have multiple comorbidities, and studies suggest that providers may receive conflicting messages from the various prevention and treatment guidelines. Moreover, while clinical pathways providing streamlined recommendations at the point-of-care may improve guideline-concordant treatment, the workload and time constraints faced by primary care practitioners remains a significant barrier to achieving optimal care.

Despite a small but statistically significant improvement in ACR testing in Calgary zone, we did not observe a meaningful improvement in guideline-concordant medical management (ACEi/ARBs and statin prescribing). While early diagnosis is critical, appropriate medical treatment is necessary to slow disease progression. Studies have similarly found low rates of CKD recognition despite high rates of screening and targeted intervention to improve CKD awareness and treatment, indicating that CKD awareness alone may not be sufficient to improve appropriate medical management.

Although several clinical pathways targeting CKD have been developed and evaluated, they mainly focus on review of initial pathway development and implementation. While pathways have been found to improve clinical outcomes and reduce complications, particularly for invasive interventions, we are not aware of any studies that have evaluated the long-term clinical or process-of-care impacts of pathways related to kidney disease care.

Strengths of our study include a population-based cohort with comprehensive health data and the use of an interrupted times series methodology, which has been recommended as a robust approach for clinical pathway evaluation. In addition, the differential uptake of the CKD pathway across the province created the opportunity to use comparison groups to strengthen the analysis. However, there are several limitations that should be acknowledged. First, it was not possible to determine which providers utilized the CKD pathway or which patients were treated according to the CKD pathway. Second, the albuminuria sub-cohort was relatively small, resulting in estimates of change in ACEi/ARB use in that cohort that had wide confidence intervals. Finally, there are limitations inherent in using administrative data – for example, disease diagnoses are based on imperfect algorithms.

**Conclusions**

In summary, following implementation of an online CKD clinical pathway, small but statistically significant improvements in ACR testing were evident in the Calgary zone, particularly among individuals without diabetes. Considering these results in combination with the differential uptake of the CKD pathway by geographical zone, the results suggest the CKD pathway may have contributed to increased ACR testing, although the association with other aspects of CKD management or clinical outcomes remains unclear. Targeted dissemination of an online clinical pathway may contribute to improvement in some aspects of medical management of CKD.

**Declarations**

**DISCLOSURES**

This study was conducted using administrative data provided by Alberta Health and Alberta Health Services. The interpretation and conclusions contained herein are those of the researchers and do not represent the views of the Government of Alberta or Alberta Health Services. Neither the Government of Alberta nor Alberta Health Services express any opinion in relation to this study.

**ETHICS APPROVAL AND CONSENT TO PARTICIPATE**

This study was approved by the Conjoint Health Research Ethics Board (CHREB) at the University of Calgary.

**CONSENT FOR PUBLICATION**

All authors have contributed to this manuscript and approve of this submission. The results presented in this paper have not been published in whole or part elsewhere.
AVAILABILITY OF DATA AND MATERIAL

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

COMPETING INTERESTS

The authors declare that they have no relevant competing or conflict of interests.

FUNDING

This study was supported by the Canadian Institutes of Health Research (CIHR).

AUTHORS CONTRIBUTIONS

All authors in this study have all contributed to this manuscript and approve of this submission. MD, BRH, RW and MS contributed to the study design and drafted the article. All authors contributed to the design and provided critical revisions to this manuscript.

References

1. Arora P, Vasa P, Brenner D, et al. Prevalence estimates of chronic kidney disease in Canada: Results of a nationally representative survey. *CMAJ*. 2013;185(9). doi:10.1503/cmaj.120833

2. Kidney Disease Improving Global Outcomes. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int*. 2013;3(1). Accessed September 21, 2020. www.publicationethics.org

3. McFarlane P, Cherney D, Gilbert RE, Senior P. Chronic Kidney Disease in Diabetes. *Can J Diabetes*. 2018;42:S201-S209. doi:10.1016/j.jcjd.2017.11.004

4. Jafar TH, Schmid CH, Levey AS. Effect of Angiotensin-Converting Enzyme Inhibitors on Progression of Nondiabetic Renal Disease. *Ann Intern Med*. 2002;137(4):298. doi:10.7326/0003-4819-137-4-200208200-00026

5. Strippoli GFM, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: Systematic review. *Br Med J*. 2004;329(7470):828-831. doi:10.1136/bmj.38237.585000.7C

6. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. *Lancet*. 2010;375(9722):1296-1309. doi:10.1016/S0140-6736(09)62004-3

7. Manns L, Scott-Douglas N, Tonelli M, et al. A Population-Based analysis of quality indicators in CKD. *Clin J Am Soc Nephrol*. 2017;12(5):727-733. doi:10.2215/CJN.08720816

8. Alberta Kidney Disease Network. *Prevalence of Severe Kidney Disease and Use of Dialysis and Transplantation Across Alberta from 2004-2013 Alberta Annual Kidney Care Report*; 2015. Accessed September 9, 2020. https://www.albertahealthservices.ca/assets/about/scn/ahs-scn-kh-annual-kidney-care-2015.pdf

9. Bello AK, Ronksley PE, Tangri N, et al. Quality of Chronic Kidney Disease Management in Canadian Primary Care. *JAMA Netw open*. 2019;2(9):e1910704. doi:10.1001/jamanetworkopen.2019.10704

10. Manns B, Tonelli M, Culleton B, et al. A cluster randomized trial of an enhanced eGFR prompt in chronic kidney disease. *Clin J Am Soc Nephrol*. 2012;7(4):565-572. doi:10.2215/CJN.12391211

11. Hemmelgarn BR, Manns BJ, Straus S, et al. Knowledge translation for nephrologists: Strategies for improving the identification of patients with proteinuria. *J Nephrol*. 2012;25(6):933-943. doi:10.5301/jn.5000226

12. Donald M, McBrien K, Jackson W, et al. Development and implementation of an online clinical pathway for adult chronic kidney disease in primary care: a mixed methods study. Published online 2016. doi:10.1186/s12911-016-0350-z

13. Curtis C, Balint C, Al Hamameh YN, et al. Online clinical pathway for managing adults with chronic kidney disease. *Can Pharm J*. 2015;148(5):257-262. doi:10.1177/1715163515597243

14. Rotter T, Kinsman L, James E, MacHotta A, Steyerberg EW. The quality of the evidence base for clinical pathway effectiveness: Room for improvement in the design of evaluation trials. *BMC Med Res Methodol*. 2012;12(1):80. doi:10.1186/1471-2288-12-80
15. Rotter T, Kinsman L, James EL, et al. Clinical pathways: effects on professional practice, patient outcomes, length of stay and hospital costs. *Cochrane Database Syst Rev*. 2010;(3). doi:10.1002/14651858.cd006632.pub2

16. Elliott MJ, Gil S, Hemmelgarn BR, et al. A scoping review of adult chronic kidney disease clinical pathways for primary care. *Nephrol Dial Transplant*. 2017;32(5):838-846. doi:10.1093/ndt/gfw208

17. Hemmelgarn BR, Clement F, Manns BJ, et al. Overview of the Alberta kidney disease network. *BMC Nephrol*. 2009;10(1):30. doi:10.1186/1471-2369-10-30

18. KDIGO. Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. *J Int Soc Neph*. 2013;3(3):1-305.

19. KDIGO. 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *J Int Soc Neph*. 2013;3(1):1-150.

20. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association Clinical Practice Guidelines for the Prevention and Management of Diabetes. *Can J Diabetes*. 2018;42(S1):S1-S325.

21. Leung AA, Daskalopoulou SS, Dasgupta K, et al. Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. *Can J Cardiol*. 2017;33:557-576. doi:10.1016/j.cjca.2017.03.005

22. Mehta SR, Bainey KR, Cantor WJ, et al. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. *Can J Cardiol*. 2018;34(3):214-233. doi:10.1016/j.cjca.2017.12.012

23. Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. *Can J Cardiol*. 2016;32(11):1263-1282. doi:10.1016/j.cjca.2016.07.510

24. Chong, C., Smekal, M., Donald, M., Elliott, M., Allu, S., Wick, J., McBrien, K., Jackson, W., Bello, A., Jindal, K., Scott-Douglas, N., Manns, B., Tonelli, M., Hemmelgarn B. Using Google Analytics to describe dissemination strategies and utilization of an online chronic kidney disease clinical pathway tool. CSN ePoster Library. May 7 2020; 289158. Published 2020. Accessed July 6, 2020. https://csnscn.multilearning.com/csnscn/2020/eposters/289158/christy.chong.using.google.analytics.to.describe.dissemination.strategies.and.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D2%2Ace_id%3D1678%2Aot_id%3D22704

25. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: Determination of prevalence and incidence using a validated administrative data algorithm. *Diabetes Care*. 2002;25(3):512-516. doi:10.2337/diacare.25.3.512

26. Quan H, Khan N, Hemmelgarn BR, et al. Validation of a case definition to define hypertension using administrative data. *Hypertension*. 2009;54(6):1423-1428. doi:10.1161/HYPERTENSIONAHA.109.139279

27. Tonelli M, Wiebe N, Fortin M, et al. Methods for identifying 30 chronic conditions: Application to administrative data Healthcare Information Systems. *BMC Med Inform Decis Mak*. 2015;15(1). doi:10.1186/s12911-015-0155-5

28. Lopez Bernal J, Cummins S, Gasparini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. *Int J Epidemiol*. Published online 2017:348-355. doi:10.1093/ije/dyw098

29. Grol R, Grimshaw J. From best evidence to best practice: Effective implementation of change in patients’ care. *Lancet*. 2003;362(9391):1225-1230. doi:10.1016/S0140-6736(03)14546-1

30. Lau R, Stevenson F, Ong BN, et al. Achieving change in primary care-effectiveness of strategies for improving implementation of complex interventions: Systematic review of reviews. *BMJ Open*. 2015;5(12):e009993. doi:10.1136/bmjopen-2015-009993

31. Bello AK, Hemmelgarn B, Lin M, et al. Impact of remote location on quality care delivery and relationships to adverse health outcomes in patients with diabetes and chronic kidney disease. *Nephrol Dial Transplant*. 2012;27(10):3849-3855. doi:10.1093/ndt/gfs267

32. Armstrong M, Weaver R, Pannu N, Services AH. *Prevalence and Quality of Care in Chronic Kidney Disease Alberta Kidney Care Report*; 2019.

33. Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: A population-level cohort study. *Lancet*. 2012;380(9844):807-814. doi:10.1016/S0140-6736(12)60572-8

34. Neale EP, Middleton J, Lambert K. Barriers and enablers to detection and management of chronic kidney disease in primary healthcare: A systematic review. *BMC Nephrol*. 2020;21(1):83. doi:10.1186/s12882-020-01731-x

35. Yamall KSH, Pollak KI, Østbye T, Krause KM, Michener JL. Primary care: Is there enough time for prevention? *Am J Public Health*. 2003;93(4):635-641. doi:10.2105/ AJPH.93.4.635
36. Østbye T, Yarnall KSH, Krause KM, Pollak KL, Gradison M, Michener JL. Is there time for management of patients with chronic diseases in primary care? *Ann Fam Med.* 2005;3(3):209-214. doi:10.1370/afm.310

37. Bello AK, Ronksley PE, Tangri N, et al. Quality of Chronic Kidney Disease Management in Canadian Primary Care. *JAMA Netw Open.* 2019;2(9):e1910704. doi:10.1001/jamanetworkopen.2019.10704

38. Junaid Nazar CM, Kindratt TB, Ahmad SMA, Ahmed M, Anderson J. Barriers to the successful practice of chronic kidney diseases at the primary health care level; a systematic review. *J Ren Inj Prev.* 2014;3(3):61-617. doi:10.12861/jrip.2014.20

39. Bansal S, Mader M, Pugh JA. Screening and Recognition of Chronic Kidney Disease in VA Health Care System Primary Care Clinics. *Kidney360.* 2020;1(9):904-915. doi:10.34067/kid.0000532020

40. Frigaard M, Rubinsky A, Lowell L, et al. Validating laboratory defined chronic kidney disease in the electronic health record for patients in primary care. *BMC Nephrol.* 2019;20(1):3. doi:10.1186/s12882-018-1156-2

41. Guessous I, McClellan W, Vupputuri S, Wasse H. Low documentation of chronic kidney disease among high-risk patients in a managed care population: A retrospective cohort study. *BMC Nephrol.* 2009;10(1):25. doi:10.1186/1471-2369-10-25

42. Plantinga LC, Tuot DS, Powe NR. Awareness of Chronic Kidney Disease Among Patients and Providers. *Adv Chronic Kidney Dis.* 2010;17(3):225-236. doi:10.1053/j.ackd.2010.03.002

43. Rothberg MB, Kehoe ED, Courtemanche AL, et al. Recognition and management of chronic kidney disease in an elderly ambulatory population. *J Gen Intern Med.* 2008;23(8):1125-1130. doi:10.1007/s11606-008-0607-z

44. Hostetter TH, Lising M. National kidney disease education program. In: *Journal of the American Society of Nephrology.* Vol 14. American Society of Nephrology; 2003:S114-S116. doi:10.1097/01.asn.0000070156.78824.c7

45. Fox CH, Brooks A, Zayas LE, McClellan W, Murray B. Primary care physicians' knowledge and practice patterns in the treatment of chronic kidney disease: An Upstate New York Practice-based Research Network (UNYNET) study. *J Am Board Fam Med.* 2006;19(1):54-61. doi:10.3122/jabfm.19.1.54

46. Owen JE, Walker RJ, Edgell L, et al. Implementation of a pre-dialysis clinical pathway for patients with chronic kidney disease. *Int J Qual Health Care.* 2006;18(2):145-151. doi:10.1093/intqhc/mzi094

47. Baker J, Rogers K, Thomas A. A patient pathway to renal replacement therapy: implementation in the progressive renal insufficiency population. *CANNT J.* 2001;11(4):18-22.

**Figures**
Figure 1
Study design.

Figure 2
Cohort diagram.
Figure 3
Segmented regression model for ACR measurement (primary outcome), by zone, including 95% confidence intervals (dashed lines). Adjusted for age, sex, eGFR category, the thirteen 28-day periods, neighborhood income quintile, rural residence, and all comorbidities in Table 1. Being logistic models, they are linear on the log(odds) scale, but are also very nearly linear on the probability scale.
Figure 4

Segmented regression models for ACR measurement (primary outcome), by zone, among those with and without diabetes. Adjusted for age, sex, eGFR category, the thirteen 28-day periods, neighborhood income quintile, rural residence, and all comorbidities in Table 1. Being logistic models, they are linear on the log(odds) scale, but are also very nearly linear on the probability scale.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementaltablesandfigures14June2021.pdf